F-1: Cellyan Biotech Files for Share Resale Amid Nasdaq Delisting Threat

Cellyan Biotechnology Co., Ltd. filed an F-1 registration statement for the resale of up to 12.5 million Class A Ordinary Shares by selling shareholders, while facing a Nasdaq minimum bid price deficiency and significant corporate governance changes.

Summary

• Cellyan Biotechnology, a Cayman Islands holding company operating through Hong Kong subsidiaries, filed to register the resale of up to 12,499,986 Class A Ordinary Shares by existing selling shareholders.
• The company will not receive any proceeds from the sale of these shares by the selling shareholders, as they were acquired in a private placement transaction on March 25, 2026, which generated approximately US$6,500,000 for the company.
• Cellyan Biotechnology received a Nasdaq notification on January 12, 2026, for failing to meet the minimum US$1.00 bid price requirement for 30 consecutive business days, with a compliance period until July 13, 2026.
• The company's business focuses on OTC pharmaceutical cross-border e-commerce supply chain services and procurement/distribution in Hong Kong, serving Mainland Chinese customers.
• Recent corporate actions include significant management and board changes in late 2025, an increase in authorized share capital, implementation of a dual-class share structure, and a share repurchase/issuance that solidified Ms. Liying Wang's control with 95.63% of voting power.
• The company fully repaid a bank loan with Livi Bank as of January 31, 2026, and is in the process of redeeming a fund investment totaling US$2,331,925, with US$1,431,925 remaining to be settled by March 31, 2026.
• As of March 26, 2026, the last reported sale price of Class A Ordinary Shares on Nasdaq was US$0.65.
• The company's auditor, Onestop Assurance PAC, is Singapore-based and subject to PCAOB inspection, mitigating some risks related to the Holding Foreign Companies Accountable Act (HFCA Act).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the immediate and significant risk of Nasdaq delisting, coupled with the highly concentrated voting power and inherent geopolitical and regulatory uncertainties associated with its Hong Kong-based operations and PRC influence. While a recent capital injection provides some liquidity, the fundamental risks to minority shareholders and the company's listing status remain high.

Positives

• The company recently completed a private placement on March 25, 2026, raising approximately US$6,500,000 in gross proceeds, significantly boosting its cash and cash equivalents to US$6,875,059 as of an adjusted September 30, 2025 basis.
• A bank loan with Livi Bank, originally due January 10, 2030, was fully repaid as of January 31, 2026, reducing long-term debt obligations.
• The company is redeeming a fund investment, with US$900,000 already received and the remaining US$1,431,925 expected by March 31, 2026, further enhancing liquidity.
• The acquisition of New Ben Global Enterprises Limited on March 18, 2026, provides a potential avenue for future business expansion.
• The company's auditor, Onestop Assurance PAC, is headquartered in Singapore and is subject to PCAOB inspection, reducing the risk of delisting under the HFCA Act compared to auditors based in Mainland China or Hong Kong.

Negatives

• The company received a Nasdaq notification on January 12, 2026, for non-compliance with the minimum US$1.00 bid price requirement, with a deadline of July 13, 2026, to regain compliance, posing a significant delisting risk.
• The current F-1 registration statement is for the resale of shares by selling shareholders, meaning the company will not receive any direct proceeds from these sales.
• Ms. Liying Wang, the largest shareholder, holds approximately 95.63% of the company's voting power, making it a controlled company and limiting the ability of other shareholders to influence corporate matters.
• As a controlled company, Cellyan Biotechnology utilizes exemptions from certain Nasdaq corporate governance requirements, potentially offering less protection to minority shareholders.
• The company has not historically declared or paid dividends and does not anticipate doing so in the foreseeable future, meaning investor returns depend solely on share price appreciation.

Risks

• Delisting from Nasdaq due to failure to meet the minimum US$1.00 bid price requirement by July 13, 2026, which could reduce liquidity, market price, and ability to raise equity financing.
• Significant control by Ms. Liying Wang (95.63% voting power) limits or precludes other shareholders' ability to influence corporate matters, potentially leading to decisions that do not align with minority interests.
• The holding company structure (Cayman Islands parent, Hong Kong subsidiaries) exposes investors to unique risks, as they do not directly own equity in the operating subsidiaries.
• Potential intervention or influence by the Chinese government on Hong Kong operations, including disallowing the corporate structure or imposing restrictions on cash transfers, which could materially change operations and devalue shares.
• Uncertainties surrounding the interpretation and enforcement of evolving PRC laws and regulations (e.g., New Overseas Listing Rules, Cybersecurity Review Measures, Data Security Law) could subject the company to new compliance requirements or regulatory actions.
• The sale of up to 12,499,986 Class A Ordinary Shares by selling shareholders in the public market could adversely affect the prevailing market price of the Class A Ordinary Shares due to increased supply.
• Intense competition in the OTC pharmaceutical cross-border e-commerce supply chain services and procurement/distribution markets.
• Reliance on a few key customers, with the loss of one or more potentially having a material adverse impact on financial performance.
• Risks associated with handling OTC pharmaceutical inventories, including quality/health issues, product damage, and transportation incidents.
• Potential failure to comply with complex applicable laws and regulations, leading to significant adverse regulatory actions or reputational harm.
• Dependence on dividends and other distributions from HK Subsidiaries for cash and financing requirements, which could be limited by future PRC government interventions or debt instruments.
• Exposure to foreign currency risk due to operations in Hong Kong and transactions in different currencies.
• Potential for future issuance of additional equity or debt securities, which could result in substantial dilution to existing shareholders and cause the share price to decline.

Future Outlook

The company intends to retain all available funds and future earnings to finance the expansion of its HK Subsidiaries' business and does not anticipate declaring or paying any dividends in the foreseeable future. It is currently evaluating options to regain compliance with Nasdaq's minimum bid price requirement by July 13, 2026. The newly acquired New Ben Global Enterprises Limited is expected to support future business expansion, though no specific activities have commenced.

Management Comments

• Management is currently evaluating available options to regain compliance with Nasdaq's minimum bid price requirement.
• We intend to retain any future earnings to finance the expansion of the HK Subsidiaries business.
• Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects and other factors the board of directors deems relevant.

Industry Context

StockSavvy.ai notes that Cellyan Biotechnology operates in the niche but growing OTC pharmaceutical cross-border e-commerce market, particularly serving Mainland Chinese consumers from Hong Kong. This sector is characterized by complex regulatory landscapes and increasing demand for overseas products. The company's focus on a 'one-stop solution' aims to address inefficiencies in traditional supply chains. However, the industry is highly susceptible to geopolitical tensions and regulatory shifts between China and Hong Kong, which could significantly impact business models and market access. The company's reliance on e-commerce platforms like Tmall and JD.com ties its growth directly to the health and regulatory environment of these platforms and the broader Chinese e-commerce sector.

Comparison to Industry Standards

• The company's dual-class share structure and controlled company status, with one shareholder holding over 95% of voting power, deviates significantly from best practices for corporate governance in many developed markets, where broader shareholder influence is encouraged. This structure is more common in founder-led tech companies or family-controlled enterprises, but for a publicly traded entity, it raises concerns about minority shareholder rights.
• The Nasdaq minimum bid price deficiency (share price of $0.65 vs. $1.00 requirement) indicates underperformance relative to listing standards, which is a critical benchmark for publicly traded companies. This situation is comparable to other small-cap companies struggling to maintain exchange listings.
• The company's business model, providing cross-border supply chain services for OTC pharmaceuticals, positions it in a specialized segment. While direct comparable companies are not explicitly named, its operational risks related to logistics, inventory, and regulatory compliance are standard for companies in the pharmaceutical distribution and e-commerce logistics sectors, though amplified by the cross-border and China/Hong Kong specific regulatory environment.

Management Changes

Corporate Governance

Related Party Transactions

• The repurchase of 7,150,000 Class A Ordinary Shares from TUTU Business Services Limited and the concurrent issuance of 7,150,000 Class B Ordinary Shares to the same entity, which is controlled by Ms. Liying Wang, the company's largest shareholder.
• A transfer of US$810,000 from Cellyan Biotechnology to Joint Cross Border Logistics Company Limited (an HK Subsidiary) as an interest-free, payable on demand loan, representing the subscription price for Class B Ordinary Shares paid by the holder of such shares.

Stakeholder Impact

• **Shareholders (especially minority Class A holders):** Face significant dilution risk from future share issuances, limited influence on corporate matters due to concentrated voting power, and potential loss of investment due to Nasdaq delisting risk. The resale of shares by selling shareholders could also depress share price.
• **Employees:** Management changes have occurred, potentially impacting internal dynamics and strategic direction.
• **Customers:** The company's ability to continue operations and provide services could be impacted by adverse regulatory changes in Hong Kong/PRC or delisting, potentially affecting service continuity.
• **Creditors:** Repayment of the Livi Bank loan is positive, but overall financial stability could be affected by operational risks and regulatory uncertainties.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by July 13, 2026.
• Selling Shareholders may offer or resell the Offered Shares from time to time through public or private transactions.
• The company expects to use the newly acquired New Ben Global Enterprises Limited to support future business expansion.
• Settle the remaining US$1,431,925 balance of the fund investment redemption on or before March 31, 2026.

Key Dates

Recommendation

A seasoned investor would likely recommend 'Sell' for Cellyan Biotechnology due to the confluence of high-impact negative factors. The immediate threat of Nasdaq delisting, coupled with the significant concentration of voting power in a single shareholder (95.63%), creates substantial governance risks and limits minority shareholder influence. Furthermore, the inherent legal and operational uncertainties stemming from its Hong Kong base and potential PRC government intervention add a layer of unpredictable geopolitical risk. While the company recently secured a private placement, this F-1 filing is for the resale of those shares, which could exert downward pressure on the stock price. The combination of delisting risk, governance concerns, and potential selling pressure outweighs the recent cash injection, making the stock a high-risk, low-conviction investment.

Keywords

Cellyan Biotechnology, SEC F-1, Share Resale, Nasdaq Delisting, OTC Pharmaceuticals, Cross-border E-commerce, Hong Kong Operations, PRC Regulatory Risk, Controlled Company, Private Placement, Corporate Governance, Supply Chain Services, Biotechnology